ATAI Life Sciences Funding: $600M Raised, IPO (2021)
ATAI Life Sciences is based in Berlin, Germany. It has raised $600M in total funding. Latest round: IPO.
ATAI Life Sciences funding overview
ATAI Life Sciences is based in Berlin, Germany. ATAI Life Sciences has raised $600M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is an IPO announced in January 2021. The round record for ATAI Life Sciences runs through 2021; nothing later has been disclosed. Investors on record include Peter Thiel, Mike Novogratz, Thor Bjorgolfsson, Steve Jurvetson. 4 distinct backers are named across the disclosed rounds.
ATAI Life Sciences at a glance
Total raised
$600M
Latest round
IPO
Latest round date
January 2021
Headquarters
Berlin, Germany
Notable investors
Peter Thiel, Mike Novogratz, Thor Bjorgolfsson, Steve Jurvetson
Frequently asked about ATAI Life Sciences funding
How much has ATAI Life Sciences raised?
ATAI Life Sciences has raised $600M in total disclosed funding across the rounds on record.
Who has invested in ATAI Life Sciences?
Peter Thiel, Mike Novogratz, Thor Bjorgolfsson, Steve Jurvetson are named among the investors backing ATAI Life Sciences.
What was the latest ATAI Life Sciences funding round?
The most recent disclosed round is an IPO, announced in January 2021.
Where is ATAI Life Sciences based?
ATAI Life Sciences is based in Berlin, Germany.
When did ATAI Life Sciences last raise?
The last disclosed ATAI Life Sciences round closed in January 2021 at IPO.
ATAI Life Sciences totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Berlin below to benchmark round size and investor mix.
